Lumos Pharma (LUMO) Set to Announce Earnings on Wednesday

Lumos Pharma (NASDAQ:LUMO) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 15th. Analysts expect Lumos Pharma to post earnings of ($1.21) per share for the quarter.

Lumos Pharma (NASDAQ:LUMO) last posted its earnings results on Thursday, March 7th. The company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.01. The firm had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.01 million. Lumos Pharma had a negative net margin of 1,659.39% and a negative return on equity of 85.63%. During the same period last year, the firm posted ($0.98) EPS. On average, analysts expect Lumos Pharma to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lumos Pharma Stock Performance

Shares of LUMO stock opened at $3.02 on Friday. Lumos Pharma has a 1 year low of $2.41 and a 1 year high of $4.55. The firm has a market cap of $24.52 million, a price-to-earnings ratio of -0.72 and a beta of 0.66. The stock’s 50-day moving average is $2.83 and its two-hundred day moving average is $3.01.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Lumos Pharma in a research note on Wednesday, March 20th.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.